Aptevo Therapeutics Files Prospectus Supplement for Up to $2.31 Million ATM Offering
Aptevo Therapeutics filed a prospectus supplement for a $2.31M ATM offering of common stock. As of October 30, it had sold 303,157 shares for $11.8M in gross proceeds. The offering is under an agreement with Roth Capital Partners and is registered under Form S-3.
How this was made
The 30-second read
Why it matters
The filing is the first public disclosure of this specific raise, adding $2.31 M to the company's financing pipeline.
Market read
A modest, first‑report capital raise with limited immediate price impact.
What to watch
Potential future larger raises or conversion of ATM shares could increase dilution.
Background
Aptevo Therapeutics (APVO) is a clinical‑stage biotech that uses its ATM facility for flexible capital raising.
Ticker impact
Aptevo Therapeutics filed a prospectus supplement to raise up to $2.31 million via its at‑the‑market offering.
minimal pressure as market prices in the modest raise
The amount is low relative to market cap; investors may view it as routine financing.
Market effects
Limited effect on biotech financing trends.
No broader regional impact.
Negligible
Counterpoint
If the raise signals cash‑flow stress, the stock could face short‑term downside.
Key entities
- companyAptevo Therapeutics
Biotech issuer of the ATM offering.
- financial_intermediaryRoth Capital Partners
Agent for the at‑the‑market offering.